Alnylam Pharmaceuticals Price Target Cut to $320.00/Share From $536.00 by Goldman Sachs

What happened

Goldman Sachs cut its price target for Alnylam Pharmaceuticals to $320.00 per share from $536.00 per share, while keeping its Buy rating on the stock unchanged.

Confirmed

Global impact / market context

A price target is the analyst's estimate of where a stock could trade in the future. Goldman still rates the stock Buy, so the cut lowers the expected upside rather than signaling a negative view. Investors reading the target should treat it as an estimate, not a guarantee, and note the size of the reduction.

Confirmed

The target cut was reported by Benzinga around 17:35 GMT. Cutting the target while keeping Buy suggests the analyst still sees value but expects less stock-price gain than before. No reason for the change, no earnings figures, and no financial details about Alnylam are provided, so the cause remains unexplained here.

Analyst inference

What to watch

1. Goldman Sachs maintains a Buy rating on Alnylam Pharmaceuticals while its price target stands at $320.00 per share after the cut. Confirmed
2. Watch for any further analyst notes or updates that explain why the price target was reduced, since the supplied article gives no stated reason for the change. Proposed
3. Watch Alnylam's future company results and financial updates, because the analyst's lower target implies expectations for future performance may have shifted. Analyst inference

Evidence

• Original source link unavailable